MoSys, Inc. Form 10-Q November 06, 2015 Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark one)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

OR

0 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

to

Commission file number 000-32929

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of Incorporation or organization) **77-0291941** (I.R.S. Employer Identification Number)

3301 Olcott Street

Santa Clara, California, 95054

(Address of principal executive office and zip code)

(408) 418-7500

(Registrant s telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer O

Non-accelerated filer O (Do not check if a smaller reporting company) Accelerated filer X

Smaller reporting company O

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of Ocober 30, 2015, 65,495,715 shares of the Registrant s common stock, \$0.01 par value, were outstanding.

FORM 10-Q

September 30, 2015

TABLE OF CONTENTS

<u>PART I</u>	FINANCIAL INFORMATION	3
<u>Item 1.</u>	Financial Statements (Unaudited):	3
	Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014	3
	Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2015 and 2014	4
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014	5
	Notes to Condensed Consolidated Financial Statements	6
<u>Item 2.</u>	Management s Discussion and Analysis of Financial Condition and Results of Operations	15
<u>Item 3.</u>	Qualitative and Quantitative Disclosures About Market Risk	21
<u>Item 4.</u>	Controls and Procedures	21
<u>PART II</u>	OTHER INFORMATION	22
Item 1.	Legal Proceedings	22
Item 1A.	Risk Factors	22
<u>Item 6.</u>	Exhibits	22
	Signatures	23

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

MOSYS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except par value)

	s	September 30, 2015	December 31, 2014
ASSETS			
Current assets			
Cash and cash equivalents	\$	1,585	\$ 3,110
Short-term investments		21,597	20,439
Accounts receivable, net		426	177
Inventories, net		1,264	881
Prepaid expenses and other		1,369	887
Total current assets		26,241	25,494
Long-term investments		2,269	2,245
Property and equipment, net		860	854
Goodwill		23,134	23,134
Other assets		756	899
Total assets	\$	53,260	\$ 52,626
LIABILITIES AND STOCKHOLDERS EQUITY			
Current liabilities			
Accounts payable	\$	378	\$ 495
Accrued expenses and other		2,057	2,350
Total current liabilities		2,435	2,845
Long-term liabilities		249	241
Commitments and contingencies (Note 4)			
Stockholders equity			
Preferred stock, \$0.01 par value; 20,000 shares authorized; none issued and outstanding			
Common stock, \$0.01 par value; 120,000 shares authorized; 65,496 shares and 49,793			
shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively		655	498
Additional paid-in capital		225,389	199,541
Accumulated other comprehensive loss		(3)	(10)
Accumulated deficit		(175,465)	(150,489)
Total stockholders equity		50,576	49,540
Total liabilities and stockholders equity	\$	53,260	\$ 52,626

The accompanying notes are an integral part of these condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except per share data)

	Three Mon Septem		Nine Months Ended September 30,			
	2015	2014	2015		2014	
Net revenue						
Product	\$ 565	\$ 437 \$	1,288	\$	1,993	
Royalty and other	457	716	1,504		2,241	
Total net revenue	1,022	1,153	2,792		4,234	
Cost of net revenue	793	447	1,593		2,046	
Gross profit	229	706	1,199		2,188	
Operating expenses						
Research and development	8,793	7,507	21,475		20,993	
Selling, general and administrative	1,547	1,689	4,711		4,976	
Total operating expenses	10,340	9,196	26,186		25,969	
Loss from operations	(10,111)	(8,490)	(24,987)		(23,781)	
Other income, net	19	30	71		115	
Loss before income taxes	(10,092)	(8,460)	(24,916)		(23,666)	
Income tax provision	13	23	60		65	
Net loss	\$ (10,105)	\$ (8,483) \$	(24,976)	\$	(23,731)	
Other comprehensive income (loss), net of tax:						
Net unrealized gains (losses) on						
available-for-sale securities	6	(17)	7		(20)	
Comprehensive loss	\$ (10,099)	\$ (8,500) \$	(24,969)	\$	(23,751)	
Net loss per share						
Basic and diluted	\$ (0.15)	\$ (0.17) \$	(0.41)	\$	(0.48)	
Shares used in computing net loss per share						
Basic and diluted	65,317	49,634	61,486		49,441	

The accompanying notes are an integral part of these condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	Nine Mont Septem			
	2015		2014	
Cash flows from operating activities:				
Net loss	\$ (24,976)	\$	(23,731)	
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation and amortization	466		313	
Stock-based compensation	2,864		3,596	
Amortization of intangible assets	293		750	
Changes in assets and liabilities:				
Accounts receivable	(249)		(27)	
Inventories	(383)		(190)	
Prepaid expenses and other assets	(624)		357	
Accounts payable	(238)		(118)	
Accrued expenses and other liabilities	(275)		339	
Net cash used in operating activities	(23,122)		(18,711)	
Cash flows from investing activities:				
Purchases of property and equipment	(369)		(289)	
Proceeds from sales and maturities of marketable securities	34,172		32,985	
Purchases of marketable securities	(35,347)		(15,859)	
Net cash (used in) provided by investing activities	(1,544)		16,837	
Cash flows from financing activities:				
Proceeds from the sale of common stock, net of issuance costs	21,368			
Proceeds from issuance of common stock	1,773		2,195	
Net cash provided by financing activities	23,141		2,195	
Net increase (decrease) in cash and cash equivalents	(1,525)		321	
Cash and cash equivalents at beginning of period	3,110		4,364	
Cash and cash equivalents at end of period	\$ 1,585	\$	4,685	

The accompanying notes are an integral part of these condensed consolidated financial statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. The Company and Summary of Significant Accounting Policies

The Company

MoSys, Inc. (the Company) was incorporated in California in September 1991, and reincorporated in September 2000 in Delaware. The Company s strategy and primary business objective is to be an IP-rich fabless semiconductor company focused on the development and sale of integrated circuit (IC) products. Prior to 2011, the Company s primary business activities were designing, developing, marketing and licensing high-performance semiconductor memory and high-speed parallel and serial interface, or SerDes, intellectual property (IP) used by the semiconductor industry and communications, networking and storage equipment manufacturers. Since 2011, the Company s proprietary high-density embedded memory with its high-speed 10 gigabits per second and higher interface technology. The LineSpeed IC product line is comprised of non-memory based, high-speed SerDes devices with gearbox or retimer functionality that convert lanes of data received on line cards or by optical modules into different configurations and/or ensure signal integrity. Both product lines are being marketed to networking and communications systems companies. The Company s future success and ability to achieve and maintain profitability depends on its success in developing a market for its ICs.

The accompanying condensed consolidated financial statements of the Company have been prepared without audit in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). The condensed consolidated balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations. The information in this report should be read in conjunction with the Company s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 or for any other future period.

Basis of Presentation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company s fiscal year is the calendar year.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.

Reclassification

Certain prior year amounts have been reclassified to conform to the current year presentation. Previously reported intangible asset amounts have been included in the other assets line item of the condensed consolidated balance sheets. The amounts for the prior periods have been reclassified to be consistent with the current year presentation and have no impact on previously reported total assets, total stockholders equity or net loss.

Cash Equivalents and Investments

The Company has invested its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company s available-for-sale short-term and long-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive loss. Realized gains and losses and declines in the value judged to be other than temporary are included in the other income, net line item in the condensed consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific identification method.

Fair Value Measurements

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date.

Level 2 Pricing is provided by third party sources of market information obtained through the Company s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company s Level 2 securities include cash equivalents and available-for-sale securities, which consisted primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company s investment advisors obtain pricing data from independent sources, such as Standard & Poor s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities.

Level 3 Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity.

Allowance for Doubtful Accounts

The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectability. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and

generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. There was no allowance for doubtful accounts receivable at either September 30, 2015 or December 31, 2014.

Inventory

Inventories are valued at the lower of cost or market. Charges for obsolete and slow moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow moving inventory items. For slow moving inventory, this analysis compares the quantity of inventory on hand to the projected sales of such inventory items. As a result of this analysis, we record an estimated charge for slow moving inventory in the form of an inventory reserve that increases cost of goods sold and decreases gross profit. When the obsolete or slow moving inventory subsequently experiences increased sales and inventory that was previously impaired is sold, cost of goods sold is decreased and gross profit is increased. Charges for the three and nine months ended September 30, 2015 were \$0.2 million.

Revenue Recognition

General

The Company generates revenue from the sales of IC products and licensing of its IP. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery or performance has occurred, the sales price is fixed or determinable, and collectability is reasonably assured. Evidence of an arrangement generally consists of signed agreements or customer purchase orders.

IC products

The Company sells products both directly to customers, as well as through distributors. Revenue from sales directly to customers is generally recognized at the time of shipment. The Company may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale. IC product revenue and costs relating to sales made through distributors with rights of return or stock rotation are generally deferred until the distributors sell the product to end customers due to the Company s inability to estimate future returns and credits to be issued. Distributors are generally able to return up to 10% of their purchases for slow, non-moving or obsolete inventory for credit every six months. At the time of shipment to distributors, an account receivable for the selling price is recorded, as there is a legally enforceable right to receive payment, and inventory is relieved, as legal title to the inventory is transferred upon shipment. Revenues are recognized upon receiving notification from the distributors that products have been sold to end customers. Distributors provide information regarding products and quantity, end customer shipments and remaining inventory on hand. The deferred margin recorded on sales to distributors where the product has not sold through to end customers is included in the accrued expenses and other line item in the condensed consolidated balance sheets.

Royalty

The Company s licensing contracts typically also provide for royalties based on the licensees use of the Company s memory technology in their currently shipping commercial products. The Company recognizes royalties in the quarter in which it receives the licensee s report.

Licensing

Licensing revenue consists of fees earned from license agreements, development services and support and maintenance. For stand-alone license agreements or license deliverables in multi-deliverable arrangements that do not require significant development, modification or customization, revenues are recognized when all revenue recognition criteria have been met. Delivery of the licensed technology is typically the final revenue recognition criteria have been met. Delivery of the licensed technology is deferred until such time as all criteria have been met. Support and maintenance revenue is recognized ratably over the period during which the obligation exists, typically 12 months. There was no licensing revenue for the three or nine months ended September 30, 2015. Licensing revenue was less than \$0.1 million for each of the three and nine months ended September 30, 2014.

Cost of Net Revenue

Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically includes engineering support to assist in the commencement of production of a licensee s products.

Goodwill

The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform the two-step impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. If the fair value of the reporting unit exceeds the carrying value of net assets of the reporting unit, goodwill is not impaired, and the Company must record an impairment charge equal to the difference. The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to assess impairment in the second step of the analysis, the price of its common stock is an important component of the fair value of the reporting unit, which can lead to potential impairment in future periods. The Company performed step one of the annual impairment test in September 2015, and concluded no factors indicated impairment of goodwill. As of September 30, 2015, the Company had not identified any factors to indicate there was an impairment of its goodwill and determined that no additional impairment analysis was required.

Per Share Amounts

Basic net loss per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and purchases under the employee stock purchase plan. As of September 30, 2015 and 2014, stock awards to purchase approximately 9,322,000 and 10,190,000 shares, respectively, were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive.

Comprehensive Loss

Comprehensive loss includes unrealized gains and losses on available-for-sale securities. Realized gains and losses on available-for-sale securities are reclassified from accumulated other comprehensive loss and included in other income, net in the condensed consolidated statements of operations and comprehensive loss. All amounts recorded in the three and nine months ended September 30, 2015 and 2014 were not considered significant.

Note 2: Fair Value of Financial Instruments

The estimated fair values of financial instruments outstanding were (in thousands):

		Septemb Unrealized	,	Unrealized	Fair
	Cost	Gains		Losses	Value
Cash and cash equivalents	\$ 1,585	\$	\$		\$ 1,585
Short-term investments:					
U.S. government-sponsored enterprise bonds	\$ 8,439	\$ 2	\$	(1)	\$ 8,440
Corporate notes	11,924			(3)	11,921
Municipal bonds	996				996
Certificates of deposit	240				240
Commercial paper					
Total short-term investments	\$ 21,599	\$ 2	\$	(4)	\$ 21,597
Long-term investments:					
Corporate notes	2,270			(1)	2,269
Total long-term investments	\$ 2,270	\$	\$	(1)	\$ 2,269

	December 31, 2014								
	Cost	Unrealized Gains	Unrealized Losses		Fair Value				
Cash and cash equivalents	\$ 3,110	\$	\$	\$	3,110				
Short-term investments:									
U.S. government-sponsored enterprise bonds	\$ 1,250	\$	\$	\$	1,250				
Municipal bonds	841				841				

Corporate notes	15,921	2	(6)	15,917
Certificates of deposit	2,430	1		2,431
Total short-term investments	\$ 20,442	\$ 3	\$ (6)	\$ 20,439
Long-term investments:				
U.S. government-sponsored enterprise bonds	\$ 1,000	\$	\$ (2)	\$ 998
Corporate notes	1,252		(5)	1,247
Total long-term investments	\$ 2,252	\$	\$ (7)	\$ 2,245

The estimated fair values of available-for-sale securities with unrealized losses were (in thousands):

	Cart	Unr	oer 30, 2015 ealized	Esta Valaa
	Cost	L	osses	Fair Value
Short-term investments:				
U.S. government-sponsored enterprise bonds	\$ 3,363	\$	(1)	\$ 3,362
Corporate notes	7,461		(3)	7,458
Total short-term investments	\$ 10,824	\$	(4)	\$ 10,820
Long-term investments:				
Corporate notes	2,270		(1)	2,269
Total long-term investments	\$ 2,270	\$	(1)	\$ 2,269

		mber 31, 2014 Inrealized	
	Cost	Losses	Fair Value
Short-term investments:			
Corporate notes	\$ 13,006	\$ (6)	\$ 13,000
Total short-term investments	\$ 13,006	\$ (6)	\$ 13,000
Long-term investments:			
U.S. government-sponsored enterprise bonds	\$ 1,000	\$ (2)	\$ 998
Corporate notes	1,252	(5)	1,247
Total long-term investments	\$ 2,252	\$ (7)	\$ 2,245

As of September 30, 2015 and December 31, 2014, all of the available-for-sale securities with unrealized losses had been in a loss position for less than 12 months.

Cost and fair value of investments based on two maturity groups were (in thousands):

			Septembe	er 30, 201	15	
		1	Unrealized	τ	Inrealized	Fair
	Cost		Gains		Losses	Value
Due within 1 year	\$ 21,599	\$	2	\$	(4)	\$ 21,597
Due in 1-2 years	2,270				(1)	2,269
Total	\$ 23,869	\$	2	\$	(5)	\$ 23,866

				Decembe	r 31, 20	14		
		Cost		Unrealized Gains	I	Unrealized Losses		Fair Value
Due within 1 year	\$	20.442	\$	3	\$	(6)	\$	20,439
Due in 1-2 years	Ŧ	2,252	Ŧ	-	-	(7)	Ŧ	2,245
Total	\$	22,694	\$	3	\$	(13)	\$	22,684

The following table represents the Company s fair value hierarchy for its financial assets (cash equivalents and investments) as of September 30, 2015 and December 31, 2014 (in thousands):

	September 30, 2015							
	Fa	ir Value		Level 1		Level 2	Level 3	
Money market funds	\$	203	\$	203	\$		\$	
U.S. government-sponsored enterprise bonds		8,440				8,440		
Corporate notes		14,190				14,190		
Municipal bonds		996				996		
Certificates of deposit		405				405		
Commercial paper		650				650		
Total assets	\$	24,884	\$	203	\$	24,681	\$	

	December 31, 2014						
	Fa	ir Value		Level 1		Level 2	Level 3
Money market funds	\$	1,837	\$	1,837	\$		\$
U.S. government-sponsored enterprise bonds		2,248				2,248	
Municipal bonds		1,243				1,243	
Corporate notes		17,164				17,164	
Certificates of deposit		2,676				2,676	
Total assets	\$	25,168	\$	1,837	\$	23,331	\$

There were no transfers in or out of Level 1 and Level 2 securities during the three or nine months ended September 30, 2015 and 2014.

Note 3. Balance Sheet Detail

	•	1ber 30,)15	De	ecember 31, 2014
		(in thou	sands)	
Inventories:				
Work-in-process	\$	1,214	\$	651
Finished goods		50		230
-	\$	1,264	\$	881

Identifiable intangible assets relating to business combinations and a patent license were (dollar amounts in thousands):

			Septem	ber 30, 20	15	
			Gross			Net
					cumulated ortization	Carrying Value
Developed technology	3-5	\$	9,240	\$	9,240	\$
Patent license	7		780		418	362
Total		\$	10,020	\$	9,658	\$ 362

		December 31, 2014								
			Gross				Net			
	Life Carrying (years) Amount				cumulated ortization		Carrying Value			
Developed technology	3-5	\$	9,240	\$	9,031	\$	209			
Patent license	7		780		334		446			
Total		\$	10,020	\$	9,365	\$	655			

Intangible assets acquired in business combinations, referred to as purchased intangible assets, are accounted for based on the fair value of assets purchased and are amortized over the period in which economic benefit is estimated to be received. The net carrying value of identifiable assets has been included in the other assets line item in the condensed consolidated balance sheets. Amortization expense has been included in research and development expense in the condensed consolidated statements of operations and comprehensive loss. The estimated aggregate amortization expense to be recognized in future years is less than \$0.1 million for the remainder of 2015 and \$0.1 million annually for 2016 through 2018.

Note 4. Commitments and Contingencies

Indemnification

In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into

indemnification agreements with its officers and directors. No material amounts were reflected in the Company s condensed consolidated financial statements for the three or nine months ended September 30, 2015 or 2014 related to these indemnifications.

The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any material payments related to these indemnification agreements.

Legal Matters

The Company is not a party to any material legal proceeding that the Company believes is likely to have a material adverse effect on its consolidated financial position or results of operations. From time to time the Company may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts.

Note 5. Business Segments, Concentration of Credit Risk and Significant Customers

The Company operates in one business segment and uses one measurement of profitability for its business. Net revenue attributed to the United States and to all foreign countries is based on the geographical location of the customer.

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, short-term and long-term investments and accounts receivable. Cash, cash equivalents and short-term and long term investments are deposited with high credit-quality institutions.

The Company recognized revenue from licensing of its technologies and shipment of ICs to customers by geographical location as follows (in thousands):

	Three Mor Septem	nths End aber 30,	ed			nths Ende nber 30,	d
	2015		2014	2015			2014
United States	\$ 507	\$	311	\$	1,233	\$	1,094
Taiwan	329		485		1,065		1,358
Japan	177		356		431		1,755
Rest of world	9		1		63		27
Total net revenue	\$ 1,022	\$	1,153	\$	2,792	\$	4,234

Customers who accounted for at least 10% of total net revenue were:

	Three Months I September 3		Nine Months September	
	2015	2014	2015	2014
Customer A	36%	*	27%	*
Customer B	32%	40%	37%	31%
Customer C	14%	27%	12%	37%
Customer D	*	10%	10%	11%

*Represents less than 10%

One customer accounted for 76% of net accounts receivable at September 30, 2015. Three customers accounted for 97% of net accounts receivable at December 31, 2014.

Note 6. Income Tax Provision

The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized.

The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. 2004 through 2014 tax years generally remain subject to examination by federal, state and foreign tax authorities. As of September 30, 2015, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

Note 7. Stock-Based Compensation

The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The unamortized compensation cost, net of expected forfeitures, as of September 30, 2015 was \$2.9 million related to stock options and is expected to be recognized as expense over a weighted average period of approximately 2.2 years. The expense related to restricted stock units (RSUs) is recognized over a three-to-five year vesting period and is based on the fair value of the underlying stock on the dates of grant. The unamortized compensation cost, net of expected forfeitures, as of September 30, 2015 was \$0.7 million related to RSUs and is expected to be recognized as expense over a weighted average period of approximately 1.6 years.

The Company presents the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options as financing cash flows in the condensed consolidated statements of cash flows. For the three and nine months ended September 30, 2015 and 2014, there were no such tax benefits associated with the exercise of stock options due to the Company s loss positions.

Valuation Assumptions

The fair value of the Company s share-based payment options for the three and nine months ended September 30, 2015 and 2014 was estimated on the grant dates using the Black-Scholes valuation option-pricing model with the following assumptions:

		Aonths Ended tember 30,		nths Ended nber 30,
Employee stock options:	2015	2014	2015	2014
Risk-free interest rate	1.4%	1.3% - 1.7%	0.6% 1.7%	1.3% 1.7%
Volatility	59.3%	53.7% 55.6%	55.7% 59.3%	53.7% 57.5%
Expected life (years)	4.0	4.0-5.0	4.0-5.0	4.0-5.0
Dividend yield	0%	0%	0%	0%

The risk-free interest rate was derived from the Daily Treasury Yield Curve Rates as published by the U.S. Department of the Treasury as of the grant date for terms equal to the expected terms of the options. The expected volatility was based on the historical volatility of the Company s stock price over the expected term of the options. The expected term of options granted was derived from historical data based on employee exercises and post-vesting employment termination behavior. A dividend yield of zero is applied because the Company has never paid dividends and has no intention to pay dividends in the near future.

The stock-based compensation expense recorded is adjusted based on estimated forfeiture rates. An annualized forfeiture rate has been used as a best estimate of future forfeitures based on the Company s historical forfeiture experience. The stock-based compensation expense will be adjusted in later periods if the actual forfeiture rate is different from the estimate.

Common Stock Options and Restricted Stock

A summary of the option and RSU activity under the Company s Amended and Restated 2000 Stock Option and Equity Incentive Plan (Amended 2000 Plan) and Amended and Restated 2010 Equity Incentive Plan (Amended 2010 Plan), referred to collectively as the Plans, is presented below (in thousands, except exercise price):

	Available for Grant	Option Number of Shares	ns Outstan	ding Weighted Average Exercise Prices
Balance at December 31, 2014	1,760	5,994	\$	3.87
Additional shares authorized under the Amended 2010 Plan	500			
Restricted stock units cancelled	6			
Options granted	(1,323)	1,323	\$	2.05
Options cancelled	153	(153)	\$	5.00
Options exercised		(22)	\$	1.60
Options expired	(78)		\$	5.79

Balance at March 31, 2015	1,018	7,142	\$ 3.52
Additional shares authorized under the Amended 2010 Plan	,	, ,	
Restricted stock units cancelled	10		
Options granted	(95)	95	\$ 2.04
Options cancelled	128	(128)	\$ 4.00
Options exercised		(40)	\$ 1.65
Options expired	(15)		\$ 4.35
Balance at June 30, 2015	1,046	7,069	\$ 3.50
Additional shares authorized under the Amended 2010 Plan			
Restricted stock units cancelled	4		
Options granted	(120)	120	\$ 1.70
Options cancelled	203	(203)	\$ 2.90
Options exercised		(20)	\$ 1.65
Options expired	(121)		\$ 2.26
Balance at September 30, 2015	1,012	6,966	\$ 3.49

The Company also has awarded options to new employees outside of the Plans and may continue to do so, as material inducements to the acceptance of employment with the Company, as permitted under the Listing Rules of the Nasdaq Stock Market. These grants must be approved by the compensation committee of the board of directors, a majority of the independent directors or, below a specified share level, by an authorized executive officer.

A summary of the inducement grant option activity is presented below (in thousands, except exercise price):

	Options Number of Shares	Outstan	ding Weighted Average Exercise Prices
Balance at December 31, 2014 and March 31, 2015	2,233	\$	3.68
Granted			
Cancelled	(2)	\$	3.86
Exercised	(512)	\$	1.55
Expired	(16)	\$	1.55
Balance at June 30, 2015	1,703	\$	4.34
Granted			
Cancelled	(28)	\$	3.57
Exercised	(6)	\$	1.50
Expired		\$	
Balance at September 30, 2015	1,669	\$	4.36

A summary of RSU activity under the Plans is presented below (in thousands, except for fair value):

	Number of Shares	Weighted Average Grant-Date Fair Value
Non-vested shares at December 31, 2014	394	\$ 4.61
Vested	(120)	\$ 4.60
Cancelled	(6)	\$ 4.60
Non-vested shares at March 31, 2015	268	\$ 4.61
Vested	(3)	\$ 4.46
Cancelled	(10)	\$ 4.62
Non-vested shares at June 30, 2015	255	\$ 4.60
Vested	(8)	\$ 4.46
Cancelled	(4)	\$ 4.62
Non-vested shares at September 30, 2015	243	\$ 4.76

The total intrinsic value of the restricted stock units outstanding as of September 30, 2015 was \$0.4 million.

The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2015 (in thousands, except contractual life and exercise price):

Range of Exercise Price	Number Outstanding	Options Outstanding Weighted Average Remaining Contractual Life (in Years)	g	Weighted Average Exercise Price	Number Exercisable	, ,	ns Exercisable Veighted A verage Exercise Price	Aggregate Intrinsic Value
\$1.68 - \$2.24	1,612	9.19	\$	2.01	261	\$	2.05	, unit
\$2.25 - \$3.15	1,429	2.94	\$	2.97	1,196	\$	2.96	
\$3.16 - \$3.80	1,483	2.90	\$	3.42	1,239	\$	3.43	
\$3.81 - \$4.34	1,435	3.33	\$	3.96	1,222	\$	3.96	
\$4.35 - \$4.69	1,386	5.58	\$	4.47	974	\$	4.46	
\$4.70 - \$6.11	1,290	2.01	\$	5.56	1,217	\$	5.57	
\$1.68 - \$6.11	8,635	4.45	\$	3.66	6,109	\$	3.98	\$
Vested and expected to vest	8,415	4.35	\$	3.69				\$
Exercisable	6,109	3.13	\$	3.98				\$

The aggregate intrinsic value of employee stock options exercised during the nine months ended September 30, 2015 and 2014 was approximately \$0.3 million and \$0.7 million, respectively.

Employee Stock Purchase Plan

In June 2010, the Company s stockholders approved the 2010 Employee Stock Purchase Plan (ESPP). A total of 2,000,000 shares of common stock were initially reserved for issuance under the ESPP in 2010. On September 1, 2010, the Company commenced the first offering period under the ESPP. On April 16, 2015, the board of directors approved an amendment to the ESPP to increase the number of shares reserved for issuance by 2,000,000 shares, subject to stockholder approval. At the Annual Meeting of Stockholders held on May 26, 2015, the Company s stockholders approved the increase. The ESPP, which is intended to qualify under Section 423 of the Internal Revenue Code, is administered by the board of directors or the compensation committee of the board of directors. The ESPP provides that eligible employees may purchase up to \$25,000 worth of the Company s common stock annually over the course of two six-month offering periods. The purchase price to be paid by participants is 85% of the price per share of the Company s common stock either at the beginning or the end of each six-month offering period, whichever is less.

On February 28, 2015, approximately 339,000 shares of common stock were issued at an aggregate purchase price of \$518,000 under the ESPP. On August 31, 2015, approximately 268,000 shares of common stock were issued at an aggregate purchase price of \$339,000 under the ESPP. As of September 30, 2015, there were approximately 2.2 million shares authorized and unissued under the ESPP.

Note 8. Stockholders Equity

On March 4, 2015, the Company sold 14,375,000 shares of common stock in an equity offering and raised approximately \$21.4 million, net of transaction expenses. Two of the Company s executive officers between them purchased a total of 406,250 shares at the public offering price.

Note 9. Related Party Transactions

In February 2012, the Company entered into a strategic development and marketing agreement with Credo Semiconductor (Hong Kong) Ltd. (Credo), a privately-funded, fabless semiconductor company, to develop, market and sell integrated circuits. Two of the Company s executive officers between them loaned a total of \$250,000 to Credo for a portion of the seed funding needed by Credo to commence its integrated circuit design efforts. These loans may be converted into minority equity interests in Credo. The strategic development and marketing agreement, as amended, calls for the Company to make payments to Credo upon Credo achieving certain development and verification milestones towards the development of IC products and provides the Company with exclusive sales and marketing rights for such IC products. As of September 30, 2015, the Company has paid Credo \$4.7 million for achievement of development milestones, as well as for mask costs and wafer purchases from third-party vendors. All amounts incurred have been recorded as research and development expenses. Currently, under the strategic development and marketing agreement, the Company is entitled to a remaining reimbursement amount of \$3.6 million of development costs based on payments made to Credo to date. This amount is subject to increase as additional payments are made to Credo. The reimbursement will be funded by the gross profits earned by the Company from the sale of the products, with the initial gross profits being primarily applied to reimbursing the Company for these development payments and a portion paid to Credo. Once the full amount has been reimbursed, the gross

profits will be shared equally by the Company and Credo.

ITEM 2. Management s Discussion and Analysis of Financial Condition and Results of Operations

This Management s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes included in this report. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which include, without limitation, statements about the market for our technology, our strategy, competition, expected financial performance and capital raising efforts, all information disclosed under Item 3 of this Part I, and other aspects of our business identified in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2015 and in other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the plans, projects, or similar expressions are intended to identify foregoing, the words believes, anticipates, expects, intends, forward-looking statements. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described below in Company Overview, Liquidity and Capital Resources; Changes in Financial Condition, Risk Factors and elsewhere in this report and under Item 1A of our annual report on Form 10-K for the year ended December 31, 2014. We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or events occur in the future.

Company Overview

Our strategy and primary business objective is to become a fabless semiconductor company focused on the development and sale of integrated circuits, or ICs, for the high-speed networking, communications, storage and computing markets. Our solutions deliver time-to-market, performance, power, area and economic benefits for system original equipment manufacturers, or OEMs. We have developed two families of ICs under the Bandwidth Engine® and LineSpeed product names. Bandwidth Engine ICs combine our proprietary 1T-SRAM® high-density embedded memory, integrated macro functions and high-speed serial interface, or SerDes, I/O, with our intelligent access technology and a highly efficient interface protocol. The LineSpeed IC product line is comprised of non-memory, high-speed SerDes I/O devices with gearbox and retimer functionality, which convert lanes of data received on line cards or by optical modules into different configurations and/or ensure signal integrity. Certain SerDes products have been developed under a strategic development and marketing agreement with Credo Semiconductor Ltd., or Credo, to whom we have paid a total of \$4.7 million for the development of these new products. The initial gross profits earned by us from the sale of Credo developed products will be primarily applied to reimbursing us for these development payments and a portion will be paid to Credo. Once a remaining \$3.6 million of this amount has been reimbursed, all gross profits from the sale of the Credo-developed products worldwide will be shared equally by Credo and us.

Historically, our primary business was the design, development, marketing, sale and support of differentiated intellectual property, or IP, including embedded memory and high-speed parallel and SerDes I/O used in advanced systems-on-chips, or SoCs. Currently, we are focused on developing differentiated IP-rich IC products and are dedicating all our research and development, marketing and sales budget to these IC products.

Our future success and ability to achieve and maintain profitability will be dependent on the marketing and sales of our IC products into networking, communications and other markets requiring high-bandwidth memory access. We are currently supporting approximately 25 existing customers, with whom we have achieved over 70 design-wins, which reflects broadening acceptance of our products. We define a design win as the point at which a customer has made a commitment to build a board against the fixed schematic for his system, and this board will utilize our IC Products. We continue to actively pursue additional design wins for the use of our ICs in networking and communication equipment. Our design wins represent the potential for significant future revenues. With limited history to date, however, we cannot estimate how much revenue each design win is likely to generate, or how much revenue all of these (and future design wins) are likely to generate. For example, our first design wins from 2012 and 2013 are starting to ramp into production, and, while we cannot predict how steep these ramps might be, we expect our revenues from them to grow in successive periods over the next few years. Another factor limiting our ability to predict future revenue levels is that, although we have established initial pricing of our IC products ordered to date, longer-term volume prices will be subject to negotiations with our customers and may vary substantially from these initial prices.

Sources of Revenue

Product. Product revenue is generally recognized at the time of shipment to our customers. An estimated allowance may be recorded, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale. IC product revenue and costs relating to sales made through distributors with rights of return and stock rotation are deferred until the distributors sell the product to end customers due to our inability to estimate future returns and credits to be issued. At the time of shipment to distributors, an account receivable for the selling price is

recorded, as there is a legally enforceable right to receive payment, inventory is relieved, as legal title to the inventory is transferred upon shipment, and the associated deferred margin is recorded as deferred revenues in the condensed consolidated balance sheets. Revenues are recognized upon receiving notification from the distributors that products have been sold to end customers.

Royalty. Royalty revenue represents amounts earned under provisions in our memory licensing contracts that require our licensees to report royalties and make payments at a stated rate based on actual units manufactured or sold by licensees for products that include our memory IP. Our license agreements require the licensee to report the manufacture or sale of products that include our technology after the end of the quarter in which the sale or manufacture occurs, and we recognize royalties in the quarter in which we receive the licensee s report. The timing and level of royalties are difficult to predict. They depend on the licensee s ability to market, produce and sell products incorporating our technology.

Licensing. Licensing revenue, which is included in royalty and other revenue, consists of fees earned from license agreements, development services, and support and maintenance. Our licensing revenue consists primarily of fees for providing circuit design, layout and design verification and granting licenses to customers that embed our technology into their products. The vast majority of our contracts allow for milestone billing based on work performed. We currently have no active license agreements generating licensing revenue.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual results may differ from these estimates, and reported results could differ under different assumptions or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2014. As of September 30, 2015, there have been no material changes to our significant accounting policies and estimates.

Results of Operations

Net Revenue.

	Septeml	oer 30,			Change	
	2015		2014		2014 to 2015	
		(dollar amounts in	thous	sands)	
Product three months ended	\$ 565	\$	437	\$	128	29%
Percentage of total net revenue	55%		38%			
Product nine months ended	\$ 1,288	\$	1,993	\$	(705)	(35)%
Percentage of total net revenue	46%		47%			

Product revenue increased for the three months ended September 30, 2015 compared with the same period of 2014 primarily due to higher shipment volumes. The decrease in product revenue for the nine months ended September 30, 2015 compared with the same period in 2014 is primarily due to lower distributor sales revenue and lower shipment volumes. Additionally, product revenue for the first nine months of 2014 included a reversal of \$0.4 million of sales return reserves, which had been recorded in prior periods.

	Septemb	ber 3(),		Change	
	2015		2014		2014 to 2015	
			(dollar amounts in	n thou	sands)	
Royalty and other three months ended	\$ 457	\$	716	\$	(259)	(36)%
Percentage of total net revenue	45%		62%			
Royalty and other nine months ended	\$ 1,504	\$	2,241	\$	(737)	(33)%
Percentage of total net revenue	54%		53%			

Royalty and other revenue include revenues generated from licensing agreements. Royalty and other revenue decreased primarily due to a decrease in shipment volumes by licensees whose products incorporate our licensed IP and a decrease in revenue recognized from residual licensing agreements entered into in prior years.

Cost of Net Revenue and Gross Profit.

		Septeml	ber 30	,		Change	
		2015		2014		2014 to 2015	
			(d	ollar amounts ir	n thous	sands)	
Cost of net revenue	three months ended	\$ 793	\$	447	\$	346	77%
Percentage of total ne	et revenue	78%		39%			
Cost of net revenue	nine months ended	\$ 1,593	\$	2,046	\$	(453)	(22)%
Percentage of total ne	et revenue	57%		48%			

Septe	ember 30,	Change
2015	2014	2014 to 2015
	(dollar amounts in th	ousands)

Gross profit three months ended	\$	229	\$	706	\$	(477)	(68)%
Percentage of total net revenue	Ψ	22%	Ψ	61%	Ψ	(,)	(00)/0
Gross profit nine months ended	\$	1,199	\$	2,188	\$	(989)	(45)%
Percentage of total net revenue		43%		52%			

Cost of net revenue is primarily comprised of direct and indirect costs related to the sale of IC products.

Cost of net revenue increased for the three months ended September 30, 2015 compared with the same period of 2014 primarily due to higher IC shipment volumes and a \$0.2 million provision for slow moving inventory. The decrease in cost of net revenue for the nine months ended September 30, 2015 compared with the same period of 2014 was primarily due to lower IC shipment volumes, partially offset by the provision for slow moving inventory recorded in the third quarter of 2015.

Gross profit decreased for the three and nine months ended September 30, 2015, compared with the same periods of 2014, primarily due to the decrease in our total revenue.

Research and Development.

	Septemb	er 30,	,		Change	
	2015		2014		2014 to 2015	
		(d	ollar amounts in	thou	sands)	
Research and development three months						
ended	\$ 8,793	\$	7,507	\$	1,286	17%
Percentage of total net revenue	860%		651%			
Research and development nine months						
ended	\$ 21,475	\$	20,993	\$	482	2%
Percentage of total net revenue	769%		496%			

Our research and development expenses include costs related to the development of our IC products and amortization of intangible assets. We expense research and development costs as they are incurred.

The increase for the three months ended September 30, 2015 compared with the same period in 2014 was primarily due to mask tooling and other fabrication costs partially offset by decreases in consulting and personnel expenses, intangible asset amortization, and stock-based compensation charges. The \$0.5 million increase for the nine months ended September 30, 2015 compared with the same period in 2014 was primarily due to increased mask tooling and other fabrication costs and personnel expenses, partially offset by decreases in consulting expenses, stock-based compensation charges in consulting expenses, stock-based compensation charges in consulting expenses, stock-based compensation charges, intangible asset amortization and software license fees.

Research and development expenses are expected to fluctuate in absolute dollars in the coming quarters, primarily due to the timing of mask tooling costs and other fabrication costs related to next generation products.

Research and development expenses included stock-based compensation expense of \$0.6 million and \$0.8 million for the three months ended September 30, 2015 and 2014, respectively. Research and development expenses included stock-based compensation expense of \$2.2 million and \$2.7 million for the nine months ended September 30, 2015 and 2014, respectively.

Selling, General and Administrative.

		Septem	ber 30,			Change	
	:	2015		2014		2014 to 2015	
			(do	llar amounts in	thous	ands)	
SG&A three months ended	\$	1,547	\$	1,689	\$	(142)	(8)%
Percentage of total net revenue		151%		146%			
SG&A nine months ended	\$	4,711	\$	4,976	\$	(265)	(5)%
Percentage of total net revenue		169%		118%			

Selling, general and administrative expenses consist primarily of personnel and related overhead costs for sales, marketing, finance, human resources and general management.

The decrease for the three months ended September 30, 2015 compared with the same period in 2014 was primarily due to reduced consulting costs and stock-based compensation charges. The decrease for the nine months ended September 30, 2015 compared with the same period in 2014 was primarily due to a decrease in stock-based compensation charges. Additionally, the 2014 periods included a reduction of expense for the sale of a domain name.

Selling, general and administrative expenses included stock-based compensation expense of \$0.2 million and \$0.3 million for the three month periods ended September 30, 2015 and 2014, respectively. Selling, general and administrative expenses included stock-based compensation expense of \$0.7 million and \$0.9 million for the nine month periods ended September 30, 2015 and 2014, respectively.

Other Income, net.

		Septemb	oer 30,			Change	
	201	15		2014		2014 to 2015	
			(do	ollar amounts in	n thou	isands)	
Other income, net three months ended	1 \$	19	\$	30	\$	(11)	(37)%
Percentage of total net revenue		2%		3%			
Other income, net nine months ended	\$	71	\$	115	\$	(44)	(38)%
Percentage of total net revenue		3%		3%			

Other income, net primarily consisted of interest income on our investments as well as foreign currency transaction activity, partially offset by other non-operating items.

Income Tax Provision.

		Septemb	oer 30,			Change	
	2015		2014	4		2014 to 2015	
			(dollar	amounts ir	n thousa	ands)	
Income tax provision three months							
ended	\$	13	\$	23	\$	(10)	(43)%
Percentage of total net revenue		1%		2%			
Income tax provision nine months ended	\$	60	\$	65	\$	(5)	(8)%
Percentage of total net revenue		2%		2%			

The provision for the three and nine months ended September 30, 2015 and 2014 was primarily attributable to taxes on earnings of our foreign subsidiaries and branches. We believe that, based on the history of our operating losses and other factors, the weight of available evidence indicates that it is more likely than not that we will not be able to realize the benefit of our net operating losses, which are primarily generated in the United States. Accordingly, a full valuation reserve has been recorded against our net deferred tax assets.

Liquidity and Capital Resources; Changes in Financial Condition

Cash Flows

As of September 30, 2015, we had cash, cash equivalents and short and long-term investments of \$25.5 million and had total working capital of \$23.8 million. Our primary capital requirements are to fund working capital, including development of our IC products, and any acquisitions that we make that require cash consideration or expenditures.

Net cash used in operating activities was \$23.1 million for the first nine months of 2015, which primarily resulted from our net loss of \$25.0 million and \$1.8 million in the net reduction in assets and liabilities, partially offset by non-cash charges, including stock-based compensation expense of \$2.9 million and depreciation and amortization expenses of \$0.8 million. The changes in assets and liabilities primarily related to the timing of the collection of receivables from customers and payments to vendors and increase in inventory.

Net cash used in operating activities was \$18.7 million for the nine months of 2014, which primarily resulted from a net loss of \$23.7 million, partially offset by non-cash charges, including stock-based compensation expense of \$3.6 million, depreciation and amortization expenses of \$1.1 million and \$0.3 million in the change in assets and liabilities. The changes in assets and liabilities primarily related to the timing of payments to vendors.

Net cash used in investing activities was \$1.5 million for the first nine months of 2015, and included net amounts transferred from cash and cash equivalents to investments of \$1.2 million, which did not impact our liquidity, and \$0.4 million for purchases of fixed assets.

Net cash provided by investing activities was \$16.8 million for the first nine months of 2014, and included net amounts transferred to cash and cash equivalents from investments of \$17.1 million, which did not impact our liquidity, partially offset by \$0.3 million for purchases of fixed assets.

Our proceeds from financing activities for the first nine months of 2015 of \$23.1 million consisted primarily of net proceeds received from the sale of common stock through a public offering and proceeds from the exercise of stock options and purchases of common stock under our employee stock purchase plan.

Our financing activities in the first nine months of 2014 primarily consisted of proceeds from the exercise of stock options and purchases of common stock under our employee stock purchase plan.

Our future liquidity and capital requirements are expected to vary from quarter to quarter, depending on numerous factors, including:

level of revenue;

٠

- cost, timing and success of technology development efforts;
- inventory levels, timing of product shipments and length of billing and collection cycles;
- fabrication costs, including mask costs, of our ICs currently under development;
- variations in manufacturing yields, materials costs and other manufacturing risks;
- costs of acquiring other businesses and integrating the acquired operations; and
- profitability of our business.

We expect our cash expenditures to continue to exceed receipts for the foreseeable future as our revenues will not be sufficient to offset our operating expenses, which include significant research and development expenditures for the expansion and fabrication of our IC products. We intend to continue our current product and research and development activities, although total expenditures on a monthly and quarterly basis will vary, primarily based on need for additional mask costs and tapeouts. Because we do not expect positive cash flows from operations in the foreseeable future, we will need to obtain additional funds to continue operating at the current level of expenditures. There can be no assurance that such funding will be available to us on favorable terms, if at all. We have an effective shelf registration statement on file with the SEC to allow us to sell up to approximately \$27 million of our securities from time to time prior to September 2017.

If we were to raise additional capital through sales of our equity securities, our stockholders would suffer dilution of their equity ownership. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness, prohibit us from paying dividends, repurchasing our stock or making investments, and force us to maintain specified liquidity or other ratios, any of which could harm our business, operating results and financial condition. If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things:

- develop or enhance our products;
- continue to expand our product development and sales and marketing organizations;
- acquire complementary technologies, products or businesses;
- expand operations, in the United States or internationally;
- hire, train and retain employees; or
- respond to competitive pressures or unanticipated working capital requirements.

Our failure to do any of these things could seriously harm our ability to execute our business strategy and may force us to curtail our research and development plans or existing operations.

Contractual Obligations

The impact that our contractual obligations as of September 30, 2015 are expected to have on our liquidity and cash flow in future periods is as follows (in thousands):

	Payment Due by Period								
	Total	Less	than 1 year	. 1	-3 years	3	-5 years	ľ	Aore than 5 years
Operating leases	\$ 3,749	\$	794	\$	1,499	\$	1,456	\$	
Software licenses	1,155		1,125		30				
	\$ 4,904	\$	1,919	\$	1,529	\$	1,456	\$	

As of September 30, 2015, our software licenses primarily related to computer-aided design software.

ITEM 3. Qualitative and Quantitative Disclosures about Market Risk

Our investment portfolio consists of money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds. The portfolio dollar-weighted average maturity of these investments is within 12 months. Our primary objective with this investment portfolio is to invest available cash while preserving principal and meeting liquidity needs. No single security should exceed 5% of the portfolio or \$2.0 million at the time of purchase. In accordance with our investment policy, we place investments with high credit-quality issuers and limit the amount of credit exposure to any one issuer. These securities, which approximated \$24.9 million as of September 30, 2015 and earned an average annual interest rate of approximately 0.3% during the first nine months of 2015, are subject to interest rate and credit risks. We do not have any investments denominated in foreign currencies, and, therefore, are not subject to foreign currency risk on such investments.

ITEM 4. Controls and Procedures

Disclosure Controls and Procedures. Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on this evaluation, our management concluded that as of September 30, 2015, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting. During the third quarter of 2015, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1. Legal Proceedings

The discussion of legal matters in Note 4 of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report under the heading Legal Matters is incorporated by reference in response to this Part II, Item 1.

ITEM 1A. Risk Factors

We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. We have disclosed a number of material risks under Item 1A of our annual report on Form 10-K for the year ended December 31, 2014, which we filed with the Securities and Exchange Commission on March 13, 2015.

ITEM 6. Exhibits

(a) Exhibits

- 31.1 Rule 13a-14 certification
- 31.2 Rule 13a-14 certification
- 32.1 Section 1350 certification
- 101 The following financial information from MoSys, Inc. s Quarterly Report on Form 10-Q for the period ended September 30, 2015, filed with the SEC on November 6, 2015, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2015 and 2014, (ii) the Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014, (iii) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014, and (iv) Notes to Condensed Consolidated Financial Statements.



Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 6, 2015

MOSYS, INC.

- By: /s/ Leonard Perham Leonard Perham President and Chief Executive Officer
- By: /s/ James W. Sullivan James W. Sullivan Vice President of Finance and Chief Financial Officer (Principal Financial Officer)

EXHIBIT INDEX

- 31.1 Rule 13a-14 certification
- 31.2 Rule 13a-14 certification
- 32.1 Section 1350 certification
- The following financial information from MoSys, Inc. s Quarterly Report on Form 10-Q for the period ended September 30, 2015, filed with the SEC on November 6, 2015, formatted in Extensible Business Reporting Language (XBRL):
 (i) the Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2015 and 2014, (ii) the Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014, (iii) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2015 and 2014, and (iv) Notes to Condensed Consolidated Financial Statements.